論文

査読有り 国際誌
2022年10月

Effect of the RNF213 p.R4810K Variant on the Progression of Intracranial Artery Stenosis

Neurology Genetics
  • Shuhei Okazaki
  • ,
  • Takeshi Yoshimoto
  • ,
  • Mariko Ohara
  • ,
  • Masatoshi Takagaki
  • ,
  • Hajime Nakamura
  • ,
  • Kotaro Watanabe
  • ,
  • Yasufumi Gon
  • ,
  • Kenichi Todo
  • ,
  • Tsutomu Sasaki
  • ,
  • Hiroyuki Araki
  • ,
  • Tomomi Yamada
  • ,
  • Shirou Manabe
  • ,
  • Haruhiko Kishima
  • ,
  • Masafumi Ihara
  • ,
  • Hideki Mochizuki

8
5
開始ページ
e200029
終了ページ
e200029
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1212/nxg.0000000000200029
出版者・発行元
Ovid Technologies (Wolters Kluwer Health)

Background and Objectives

Intracranial artery stenosis is the predominant etiology of ischemic stroke in the Asian population. Furthermore, the presence of the RNF213 p.R4810K variant, which is a susceptibility gene for moyamoya disease, increases the risk of ischemic stroke attributable to large-artery atherosclerosis. Accordingly, we hypothesized that this genetic variant may affect the long-term outcome of intracranial artery stenosis in the East Asian population. We thus aimed to examine the effect of this variant on the long-term progression and prognosis of intracranial artery stenosis.

Methods

Using a prospective database, we identified adult patients with intracranial artery stenosis who underwent periodic MRI examinations for >5 years. We evaluated stenosis progression using a validated visual grading system. We excluded patients diagnosed with moyamoya disease at the time of initial MRI. Genotyping of RNF213 p.R4810K was performed at the end of the follow-up period.

Results

Among 52 eligible patients, 22 (42%) were carriers of the RNF213 p.R4810K variant. The median follow-up duration was 10.3 years. During the follow-up period, progression of intracranial artery stenosis was observed in 64% variant carriers and 27% noncarriers. There was a significant association of the variant with time to progression of intracranial artery stenosis (hazard ratio [HR] 3.31, 95% CI 1.38–7.90, p = 0.007), and time to the composite endpoint of symptomatic stroke and transient ischemic attack (HR 3.70, 95% CI 1.15–11.86, p = 0.028), but not to symptomatic stroke alone (HR 2.18, 95% CI 0.62–7.74, p = 0.23). Two variant carriers with progression were newly diagnosed with moyamoya disease.

Discussion

Our findings indicated that the RNF213 p.R4810K variant increases the risk of intracranial artery stenosis progression.

リンク情報
DOI
https://doi.org/10.1212/nxg.0000000000200029
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36324634
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621605
URL
https://syndication.highwire.org/content/doi/10.1212/NXG.0000000000200029
ID情報
  • DOI : 10.1212/nxg.0000000000200029
  • eISSN : 2376-7839
  • PubMed ID : 36324634
  • PubMed Central 記事ID : PMC9621605

エクスポート
BibTeX RIS